GlobeImmune files for $69 million IPO to fund cancer/infection immunotherapies
This article was originally published in Scrip
GlobeImmune wants to raise $69 million in an initial public offering to fund development of its oncology and infectious disease immunotherapies before it runs out of cash around the end of 2012. The company did not indicate how many shares it will sell, or at what price.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.